Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission

NCT03333369 | Completed Early Phase 1

• 1 other identifier: DA_EE_Salience
• Study Type: interventional
• Target: 65
• Locations: 1 country
• Sites: 1

Brief Summary

The dopamine hypothesis of schizophrenia implies that alterations in the dopamine system cause functional abnormalities in the brain that may converge to aberrant salience attribution and eventually lead to psychosis. Indeed, widespread brain disconnectivity across the psychotic spectrum has been revealed by resting-state functional magnetic resonance imaging (rs-fMRI). However, the dopaminergic involvement in intrinsic functional connectivity (iFC) and its putative relationship to the development of psychotic spectrum disorders remains partly unclear - in particular at the low-end of the psychosis continuum. Therefore, the investigators examined dopamine-induced changes in striatal iFC and their modulation by psychometrically assessed schizotypy. The randomized, double-blind placebo-controlled study design included 54 healthy, right-handed male participants. Each participant was assessed with the Schizotypal Personality Questionnaire (SPQ) and underwent 10 min of rs-fMRI scanning. Participants then received either a placebo or 200 mg of L-DOPA, a dopamine precursor. The investigators analyzed iFC of six striatal seeds that are known to evoke modulation of dopamine-related networks. The investigators hypothesized that, within the L-DOPA treatment group, the striatal iFC would be disrupted due to increased availability of dopamine. The investigators further hypothesized that individuals with high schizotypal scores would show a disruption of striatal connectivity, as has been reported with schizophrenia. In addition, the investigators hypothesized that the L-DOPA-dependent change in striatal iFC would interact with the severity of positive symptoms, as has been found in previous studies in non-clinical psychosis. The investigators anticipated this symptom-dependent change, especially in the ventral striatal regions, because these are thought to modulate cortico-striatal loops associated with cognition and emotion.

Conditions

Healthy; Schizotypal Personality

Keywords

resting-state functional MRI; Dopamine; functional connectivity

Outcome Measures

Primary Outcomes (1)

• intrinsic functional connectivity

  Dopamine dependent intrinsic functional connectivity as measured by resting-state functional magnetic resonance imaging

  2 hours

Secondary Outcomes (1)

• Schizotypy

  15 min

Study Arms (2)

Madopar Arm

ACTIVE COMPARATOR

A single dose of a cachet filled with 200 mg levodopa/50 mg benserazide

Drug: 200 mg levodopa/50 mg benserazide

Placebo Arm

PLACEBO COMPARATOR

A single dose of a cachet filled with Dextrose

Drug: Dextrose

Interventions

200 mg levodopa/50 mg benserazide DRUG

Also known as: Madopar DR

Madopar Arm

Dextrose DRUG

Also known as: Placebo

Placebo Arm

Eligibility Criteria

• Age: 20 Years - 60 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy,
• Between 20 and 40 years of age,
• With exceptional experiences or skeptics,
• Caucasian origin,
• Normal visual and acoustic accuracy.

You may not qualify if:

• Persons with a personal or first-degree family history of neurological and psychiatric disease, including impaired cognitive abilities,
• Pregnant or breastfeeding women,
• Chronic or acute pain,
• Acute or chronic somatic disease,
• Women (i.e. only men included),
• Men over 40 years of age or below 20,
• left- or mixed-handedness,
• Hormonal or herbal therapy,
• Smoker.

Sponsors & Collaborators

• University of Zurich: lead
• Swiss Federal Institute of Technology: collaborator

Study Sites (1)

Collegium Helveticum, ETH & Universität Zürich

Zurich, 8006 Zürich, Switzerland

Location

MeSH Terms

Conditions

Schizotypal Personality Disorder

Interventions

benserazide, levodopa drug combination; Glucose

Condition Hierarchy (Ancestors)

Personality Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Hexoses; Monosaccharides; Sugars; Carbohydrates

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Masking Details: For the randomization of the intervention and placebo the "Research Randomizer" on www.randomizer.org will be used. The randomization will be performed by the Kantonsapotheke in Zurich. The generated list of condition sequences will be stored at there. The list will not be accessible for study members who are associated with the assessment. The Boxes containing the cachets will be labelled with the subject number and A or B for the first or second session, respectively as well as with the ID of the study. The cachets will be prepared and labelled at the Kantonsapotheke in Zurich. DA and placebo will be provided in identical cachets. The blinding will be broken only after a subject has completed both experimental sessions or in case of an acute reaction during the session.
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Each subject in the group will participate in two test sessions, separated by at least one week. All sessions will start at 15:30. In a double-blind within-design procedure, participants will be randomly assigned to receive either a cachet of a dual-release formulation of 200 mg levodopa/50 mg benserazide (a peripheral L-dihhydroxyphenylalanine-decarboxylase inhibitor) or a placebo in the first session. In the second session they will receive the other intervention.

Study Record Dates

• First Submitted: October 30, 2017
• First Posted: November 6, 2017
• Study Start: May 15, 2014
• Primary Completion: August 13, 2015
• Study Completion: August 13, 2015
• Last Updated: November 6, 2017

Record last verified: 2017-11

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)